Arkansas-based Lexicon Inc. and its divisions have earned five safety awards from the American Institute of Steel ...

In the assessment of 12-month price targets, analysts unveil insights for Lexicon Pharmaceuticals, presenting an average target of $3.83, a high estimate of $6.00, and a low estimate of $1.00. This ...

Lexicon Pharmaceuticals, Inc.’s LXRX share price has surged by 77.50%, which has investors questioning if this is right time to sell.

Lexicon Pharmaceuticals shares jumped nearly 75% in early trading Friday after the biopharmaceutical company inked a license agreement potentially worth $1 billion with Danish drug maker Novo Nordisk.

Lexicon Pharmaceuticals, Inc.’s LXRX share price has dipped by 25.32%, which has investors questioning if this is right time to buy.

Lexicon's stock rose 60% after securing a potential $1 billion deal with Novo Nordisk for the preclinical obesity drug LX9851. The company abandoned its underperforming heart failure drug and ...

THE WOODLANDS, Texas, April 02, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a presentation at the 24th Annual ...

March 28 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab is licensing Lexicon Pharmaceuticals' (LXRX.O), opens new tab experimental obesity drug in a deal worth up to $1 billion, the Danish ...

New features emphasize flexible solutions to meet changing workforce mobility priorities Our redesigned website isn't just about aesthetic ...

(Reuters) -Novo Nordisk is licensing Lexicon Pharmaceuticals' experimental obesity drug in a deal worth up to $1 billion, the Danish drugmaker's second deal this week, as it looks to strengthen ...